HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Jubilant Pharmova Ltd Stock Comparison

Alivus Life Sciences Ltd vs Jubilant Pharmova Ltd Stock Comparison

Last Updated on: Dec 18, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 900.2 as of 18 Dec 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 4.4 on March 2020 to 16.8 on March 2025 . This represents a CAGR of 25.02% over 6 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 3964 crore on March 2020 to ₹ 14220 crore on March 2025 . This represents a CAGR of 23.73% over 6 years.
  • The revenue of Alivus Life Sciences Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Jubilant Pharmova Ltd for the Sep '25 is ₹ 1976 crore as compare to the Jun '25 revenue of ₹ 1912 crore. This represent the growth of 3.32%.
  • The ebitda of Alivus Life Sciences Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Jubilant Pharmova Ltd for the Sep '25 is ₹ 345.3 crore as compare to the Jun '25 ebitda of ₹ 301.5 crore. This represent the growth of 14.53%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The net profit of Jubilant Pharmova Ltd changed from ₹ 6 crore to ₹ 119.9 crore over 10 quarters. This represents a CAGR of 231.33% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 24.8 % on March 2020 to 414.06 % on March 2025 . This represents a CAGR of 59.87% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Jubilant Pharmova Ltd

  • Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
  • The Company name was thereafter changed to 'Jubliant Organosys Limited' in November, 2001 and to 'Jubilant Life Sciences Limited' in October, 2009 and the Company attained its new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
  • The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
  • The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

Alivus Life Sciences Ltd News Hub

News

Alivus Life Sciences announces board meeting date

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 6 Nov...

Read more

30 Oct 2025 10:27

News

Alivus Life Sciences to conduct AGM

Alivus Life Sciences announced that the Annual General Meeting(AGM) of the company will be...

Read more

12 Aug 2025 12:09

News

Alivus Life Sciences to declare Quarterly Results

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Aug...

Read more

25 Jul 2025 11:06

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

Jubilant Pharmova Ltd News Hub

News

Jubilant Pharmova appoints Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc.

Jubilant Pharmova has appointed Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc. st...

Read more

02 Dec 2025 09:39

News

Board of Jubilant Pharmova approves grant of 1,506 stock options

The board of Jubilant Pharmova at its meeting held on 31 October 2025 has approved the Gra...

Read more

31 Oct 2025 14:44

News

Jubilant Pharmova to discuss results

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 31 Octob...

Read more

15 Oct 2025 09:34

News

Jubilant HollisterStier expands its sterile injectable manufacturing capacity at Spokane unit in the US

Jubilant Pharmova announced today that Jubilant HollisterStier LLC (JHS)'a wholly owned su...

Read more

10 Oct 2025 09:51

News

Jubilant Pharmova appoints Arun Kumar Sharma as CFO

'The appointment is made for an interim period to ensure a smooth transition to the new CF...

Read more

23 Sep 2025 12:39

News

Jubilant Pharmova's step-down subsidiary completes US FDA audit with no observations

Jubilant Cadista is a subsidiary of Jubilant Pharma, which is the wholly owned subsidiary ...

Read more

22 Sep 2025 10:01

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Jubilant Pharmova Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Jubilant Pharmova Ltd?

Market cap of Alivus Life Sciences Ltd is 11,043 Cr while Market cap of Jubilant Pharmova Ltd is 16,780 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Jubilant Pharmova Ltd?

The stock performance of Alivus Life Sciences Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Jubilant Pharmova Ltd?

As of December 18, 2025, the Alivus Life Sciences Ltd stock price is INR ₹900.2. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹1053.4.

How do dividend payouts of Alivus Life Sciences Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions